Results and Takeaways From a 12-month Claims Analysis of Ruxolitinib
Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, reduced rescue medication use, fewer dermatology visits, and a favorable safety profile compared to standard treatments, supporting its role as a valuable non-steroidal topical option for long-term management.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
